Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects

NCT02824666 is registered in ClinicalTrials.gov with Braeburn Pharmaceuticals as lead sponsor.

NCT NCT02824666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02824666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects
Lead sponsor
Braeburn Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2016
Completion date
November 8, 2016
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia